Issued on behalf of LIXTE Biotechnology Holdings, Inc. Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power ...

Love me some great news on a Friday afternoon. Very glad people are getting the word out and taking this seriously, because once they put one of these things in your neck of the woods, you're unlikely ...

Lets geek out. The HackerNoon library is now ranked by reading time created. Start learning by what others read most. Lets geek out. The HackerNoon library is now ranked by reading time created. Start ...

Kirk McKeown, co-founder and CEO of Carbon Arc, breaks down why data, not just AI models, will determine the next wave of innovation in wealth management. As firms race to adopt AI, the real challenge ...

Long-term preservation of digital information has long challenged archivists and datacenters, as magnetic tapes and hard drives degrade within decades. Existing archival storage solutions have limited ...

Forbes contributors publish independent expert analyses and insights. This is the second in a set of four blogs about projections for digital storage and memory for the following year that we have ...

Forbes contributors publish independent expert analyses and insights. For several years I have written a series of articles outlining my projections for various digital storage and non-volatile memory ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

One way of viewing efforts by storage suppliers to move into data management over the past couple of years is that storage technology is emerging from the backroom and wants to be at the centre of ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...